- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01214668
Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
A Phase 1b, Multicenter, Dose-Escalation Study of LY573636-sodium in Combination With Liposomal Doxorubicin in Patients With Advanced Solid Tumors
The goal of this study is to determine the dose of LY573636-sodium (hereafter referred to as LY573636) that can be administered safely in combination with liposomal doxorubicin in patients with advanced cancer who have failed a prior treatment.
The study consists of a dose escalation phase to the maximum tolerated dose (MTD) and a dose confirmation phase in patients with platinum resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have never been treated with doxorubicin.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
Arizona
-
Scottsdale, Arizona, Spojené státy, 85258
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
California
-
Encinitas, California, Spojené státy, 92024
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Tennessee
-
Memphis, Tennessee, Spojené státy, 38119
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Washington
-
Seattle, Washington, Spojené státy, 98195
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- You must have a histologically confirmed solid malignancy that is unresectable and/or metastatic which has progressed after receiving standard approved chemotherapy
- You must have a solid malignancy for which an anthracycline-based regimen is felt to be a reasonable treatment option
- You must have measurable disease or non-measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST)
- You must have a serum albumin level greater than or equal to 3.0 grams/deciliter (g/dL) (30 g/L)
- You must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- You must have tumor progression after receiving standard/approved chemotherapy
- You must be reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures
- Women must be sterile, post-menopausal or on a contraception and men must be sterile or on contraception
- Your test results assessing the function of your blood, kidneys, liver, and heart are satisfactory
- Ovarian patients in the confirmation phase must have failed to achieve at least a partial response to a first-line platinum-based therapy (platinum-refractory) or have progression in less than 6 months after a response to a first-line platinum-based therapy (platinum-resistant)
- Ovarian patients in the confirmation phase must have measurable disease by RECIST
- Ovarian patients in the confirmation phase must be liposomal doxorubicin or doxorubicin naive and not amendable to curative therapy
Exclusion Criteria:
- You cannot have received other investigational drugs within the last 28 days
- You cannot have other on-going serious illnesses including active bacterial, fugal, or viral infections
- You cannot have current hematologic malignancies, acute or chronic leukemia, or brain metastasis
- You cannot currently be receiving warfarin (Coumadin®) therapy
- You cannot have known positive test results in human immunodeficiency, hepatitis B surface antigen or hepatitis C antibodies
- You cannot have a history of cardiac disease or clinical evidence of congestive heart failure
- Ovarian patients in the confirmation phase who have received 2 or more cytotoxic regimens for platinum-resistant disease
- You cannot currently be receiving amiodarone, quinidine, propofol, and clozapine
- If you are taking esomeprazole or pantoprazole you must be able to stop taking this medication within 72 hours before and after LY573636 administration
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Intervenční model: Sekvenční přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: LY573636 + Liposomal Doxorubicin
|
Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met.
Ostatní jména:
40 mg/m² on Day 1, given intravenously of each 28-day cycle Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Recommended Phase 2 Dose
Časové okno: Predose up to 28 days postdose in Cycle 1
|
Recommended Phase 2 dose was determined by maximum tolerated dose (MTD), which is corrected for the participant's predose albumin to identify the albumin-corrected exposure range of LY 573636 when combined with liposomal doxorubicin.
MTD is the highest dose with <33% of participants having a dose-limiting toxicity (DLT) in the first 28-day cycle of treatment.
DLT is an adverse event (AE) that is likely related to the study drug or combination and fulfills any 1 of the following: Common Terminology Criteria for AE (CTCAE, Version 3.0) Grade (Gr) 4 hematologic toxicity; Gr 3 nonhematologic toxicity (excluding controllable nausea/vomiting or diarrhea and alopecia); Gr 3 electrolyte toxicity that is not resolved with standard treatments.
Those who enter the study with Gr 2 hepatic enzyme abnormalities, DLT for an isolated Gr 3 hepatic enzyme abnormality is determined by investigators; a DLT can be declared if a participant experiences increasing toxicity during treatment.
|
Predose up to 28 days postdose in Cycle 1
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Number of Participants With Clinically Significant Events
Časové okno: Baseline to study completion up to 18.49 months
|
Clinically significant events are defined as serious adverse events (SAEs), regardless of causality, during the study including the 30-day follow-up period.
A summary of SAEs and other nonserious adverse events is located in the Reported Adverse Event section.
Death due to progressive disease was not considered as an SAE.
|
Baseline to study completion up to 18.49 months
|
Pharmacokinetics: Maximum Concentration (Cmax) of LY573636
Časové okno: Predose, 30 minutes (min), 2 hours (h), 4 h, 166 h, 360 h and 698 h postdose in Cycle 1; Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 2; Predose, 166h, 360h and 698 h postdose in Cycle 3
|
Predose, 30 minutes (min), 2 hours (h), 4 h, 166 h, 360 h and 698 h postdose in Cycle 1; Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 2; Predose, 166h, 360h and 698 h postdose in Cycle 3
|
|
Number of Participants With Tumor Response
Časové okno: Baseline to measured progressive disease up to 4.7 months
|
Number of participants with tumor response = number of participants with complete response (CR) + number of participants with partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines.
CR is the disappearance of all target and non-target lesions; PR is a ≥30% decrease in the sum of longest diameter of target lesions.
|
Baseline to measured progressive disease up to 4.7 months
|
Pharmacokinetics: Area Under the Curve of LY573636 Above the Albumin Corrected Threshold (AUCalb)
Časové okno: Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 1; Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 2; Predose, 166h, 360h and 698 h postdose in Cycle 3
|
LY573636 has been found to be highly bound to albumin.
AUCalb is a surrogate measure of exposure to unbound (free) LY573636.
|
Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 1; Predose, 30 min, 2 h, 4 h, 166 h, 360 h and 698 h postdose in Cycle 2; Predose, 166h, 360h and 698 h postdose in Cycle 3
|
Další výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Number of Participants Who Died Due to Progressive Disease During the 30 Days Following Discontinuation From Study Treatment
Časové okno: From date of randomization until up to 30 days post study treatment discontinuation, assessed up to 4.7 months
|
From date of randomization until up to 30 days post study treatment discontinuation, assessed up to 4.7 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Call 1-877-CTLILLY (1-877-285-4559) or 317-651-4559 Mon. - Fri. 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 12887
- H8K-MC-JZAN (Jiný identifikátor: Eli Lilly and Company)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Solidní nádory
-
SanofiDokončenoAdvance Solid TumorsJaponsko
-
Novartis PharmaceuticalsDokončenocMET Dysegulation Advanced Solid TumorsRakousko, Dánsko, Švédsko, Spojené království, Španělsko, Německo, Holandsko, Spojené státy
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdNáborKRAS G12C Mutant Advanced Solid TumorsČína
-
AmgenAktivní, ne náborKRAS p.G12C Mutant Advanced Solid TumorsSpojené státy, Francie, Kanada, Španělsko, Belgie, Korejská republika, Rakousko, Austrálie, Maďarsko, Řecko, Německo, Japonsko, Rumunsko, Švýcarsko, Brazílie, Portugalsko
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NeznámýMSI-H nebo dMMR Advanced Solid TumorsČína
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; National Cancer Institute (NCI)NáborRefrakterní MSI - H Solid Tumors Před terapií PD-(L) 1 | Nádory MSI-HSpojené státy
-
Merrimack PharmaceuticalsDokončenoMetastatický karcinom prsu | Her2 Amplified Solid TumorsSpojené státy
-
Novartis PharmaceuticalsNantCell, Inc.UkončenoPIK3CA mutované pokročilé solidní nádory | PIK3CA Amplified Advanced Solid TumorsŠpanělsko, Belgie, Spojené státy, Kanada
-
Nationwide Children's HospitalAktivní, ne nábor
-
Varian, a Siemens Healthineers CompanyZatím nenabíráme
Klinické studie na LY573636-sodium
-
Eli Lilly and CompanyDokončenoAkutní myeloidní leukémie | Esenciální trombocytémieSpojené státy
-
Eli Lilly and CompanyDokončenoRakovina vaječníků | Rakovina vejcovodů | Primární peritoneální rakovinaItálie, Spojené státy, Ruská Federace
-
Eli Lilly and CompanyDokončenoMetastatický melanomAustrálie, Spojené státy
-
Eli Lilly and CompanyDokončenoSarkom, měkká tkáňSpojené státy, Španělsko, Argentina
-
Eli Lilly and CompanyDokončeno
-
Eli Lilly and CompanyUkončenoLymfom | Pokročilá rakovinaSpojené království
-
Eli Lilly and CompanyDokončenoNemalobuněčný karcinom plicNěmecko, Itálie
-
Eli Lilly and CompanyUkončenoMelanomSpojené státy, Itálie, Austrálie, Španělsko, Francie, Holandsko, Spojené království, Rakousko, Polsko, Německo, Belgie, Tchaj-wan, Kanada, Finsko, Izrael, Korejská republika, Norsko, Švédsko
-
Eli Lilly and CompanyUkončeno